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ABSTRACT

Introduction We compared diabetes incidence in South
Asians aged ≥45 years in urban India (Chennai and Delhi)
and Pakistan (Karachi), two low-income and middle-
income countries undergoing rapid transition, with blacks
and whites in the US, a high-income country.
Research design and methods We computed age-
specific, sex-specific and body mass index (BMI)-specific
diabetes incidence from the prospective Center for
Cardiometabolic Risk Reduction in South Asia Study
(n=3136) and the Atherosclerosis Risk in Communities
Study (blacks, n=3059; whites, n=9924). We assessed
factors associated with incident diabetes using Cox
proportional hazards regression.
Results South Asians have lower BMI and waist
circumference than blacks and whites (median BMI, kg/
m2: 24.9 vs 28.2 vs 26.0; median waist circumference,
cm 87.5 vs 96.0 vs 95.0). South Asians were less insulin
resistant than blacks and whites (age-BMI-adjusted
homeostatic model assessment of insulin resistance,
µIU/mL/mmol/L: 2.30 vs 3.45 vs 2.59), and more insulin
deficient than blacks but not whites (age-BMI-adjusted
homeostasis model assessment of β-cell dysfunction,
µIU/mL/mmol/L: 103.7 vs 140.6 vs 103.9). Age-
standardized diabetes incidence (cases/1000 person-
years (95% CI)) in South Asian men was similar to black
men and 1.6 times higher (1.37 to 1.92) than white men
(26.0 (22.2 to 29.8) vs 26.2 (22.7 to 29.7) vs 16.1 (14.8
to 17.4)). In South Asian women, incidence was slightly
higher than black women and 3 times (2.61 to 3.66) the
rate in white women (31.9 (27.5 to 36.2) vs 28.6 (25.7
to 31.6) vs 11.3 (10.2 to 12.3)). In normal weight (BMI
<25 kg/m2), diabetes incidence adjusted for age was 2.9
times higher (2.09 to 4.28) in South Asian men, and 5.3
times (3.64 to 7.54) in South Asian women than in white
women.
Conclusions South Asian adults have lower BMI and
are less insulin resistant than US blacks and whites,
but have higher diabetes incidence than US whites,
especially in subgroups without obesity. Factors other
than insulin resistance (ie, insulin secretion) may play an
important role in the natural history of diabetes in South
Asians.

Significance of this study
What is already known about this subject?
►► South Asians exhibit high prevalent type 2 diabetes,

even at low body mass indices (BMI).
►► Few longitudinal studies have compared incident

diabetes in South Asians with other ethnic groups,
across BMI distributions, and including measures
of pathophysiology (insulin resistance, insulin
secretion).

What are the new findings?
►► Compared with US whites, South Asians experienced

higher rates of incident diabetes, especially in subgroups without obesity.
►► South Asians were less insulin resistant than comparable US blacks and whites.
►► South Asians were more insulin deficient than US
blacks and whites.

How might these results change the focus of
research or clinical practice?
►► Findings will influence screening guidelines, preven-

tion and therapeutic regimens for South Asians with
type 2 diabetes, especially people without obesity,
with a focus on primarily targeting improvements in
insulin secretion.

INTRODUCTION
South Asians, defined as people residing in
or with origins in India, Pakistan, Bangladesh, Sri Lanka, Nepal, Bhutan and Maldives,
comprise nearly 2 billion people globally
(nearly 30% of the world population), and
experience a high risk of developing type 2
diabetes.1–4 This phenomenon, first observed
in the diaspora who migrated to higher-
income countries,5–7 has become acutely
evident in the past few decades with urbanization and industrialization of low-income and
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middle-income countries, and with the dramatic rise in
diabetes prevalence within South Asia itself, particularly
in cities.8–12
A number of studies comparing South Asians with
other groups have reported a higher diabetes prevalence
in this population after accounting for age and body mass
index (BMI).2 13–15 However, data on the incidence of
diabetes in South Asians living in South Asia are limited.
A few studies in urban South Asia have documented high
incidence of type 2 diabetes in South Asians.16 17 Studies
in Canada and the USA1 18 19 have revealed a higher incidence of type 2 diabetes in South Asians, compared with
Chinese, whites and blacks. However, prior studies have
not had long duration or rigorous follow-up for incident
diabetes and have lacked in population representativeness or in measures of insulin resistance and secretion.
Using data from the Center for Cardiometabolic Risk
Reduction in South Asia Study (CARRS), we report the
age-specific and BMI-specific incidence by sex for urban
South Asians adults living in India and Pakistan. We
compared diabetes incidence among South Asians (aged
≥45 years) (n=3136) from CARRS with blacks (n=3059)
and whites (n=9924) aged 45–64 years in the USA using
data from the Atherosclerosis Risk in Communities
(ARIC) study.
METHODS
Details of methods used in CARRS and ARIC20 21 are
published elsewhere. Brief descriptions of study population, harmonized analytical samples and measurements
are provided below.
Study populations and analytical samples
Center for Cardiometabolic Risk Reduction in South Asia Study
CARRS is a representative sample of adult residents living
in Chennai and Delhi (India) and Karachi (Pakistan),
recruited in 2010–11, and followed for assessments in
2012–13, 2013–14, 2014 and 2016–17. The first, second
and fourth assessments were conducted in person and
the third by telephone. As reported previously,20 CARRS
used a population-
based, multistage, cluster sampling
design based on local administrative boundaries to
recruit adult men and women to be representative of
each city. At the first stage of sampling, 20 wards were
randomly selected from the urban districts of each city.
At the second stage of sampling, five census enumeration blocks (CEBs) were selected. At the third stage,
20 households were randomly selected. And the fourth
and final stage, one age-eligible man and non-pregnant
woman from each household was randomly selected
using the Kish method. The participants with equal age-
sex strata (20–45, 46–60, ≥60 years) were selected. The
baseline data were collected on n=16 287 participants
aged ≥20 years, however we analyzed only those whose
age was ≥45 years at baseline in order to be comparable
to ARIC (ie, excluded those <45 years, n=6853). The
present analysis includes participants with baseline data
2

collected between October 2010 and December 2011,
excluding those with diabetes at baseline (n=2541) and/
or those with missing diabetes status (n=70). Participants
with at least one follow-up assessment by February 2017
(n=3136) were included. Median follow-up time (IQR)
was 4.8 (3.8–5.1) years. Diabetes at baseline was defined
as fasting plasma glucose (FPG) ≥7.00 mmol/L (126 mg/
dL), hemoglobin A1c (HbA1c) ≥6.5% (48 mmol/mol)
or self-reported/physician diagnosed diabetes or glucose
lowering medication use. A total of 2205 participants had
impaired glucose tolerance (ie, FPG ≤100–125 mg/dL or
HbA1c ≤5.7%–6.5%) at baseline.
Atherosclerosis Risk in Communities
The ARIC study is an ongoing, community-based cohort
of 15 792 adults recruited from four communities in
the USA: Forsyth County, North Carolina; Washington
County, Maryland; suburbs of Minneapolis, Minnesota
and Jackson, Mississippi. The ARIC Cohort Component
began in 1987, and each ARIC field center randomly
selected and recruited a cohort sample of approximately
4000 individuals aged 45–64 years from a defined population in their community, to receive extensive examinations, including medical, social and demographic data.
Follow-
up also occurs semi-
annually, by telephone, to
maintain contact and to assess health status of the cohort.
The first examination was done between 1987 and 1989
when participants were aged 45–64 years. For these
analyses, visit 1 (1987–1989) was baseline with follow-up
through visit 4 (1996–1998) (median follow-up time: 8.8
years, IQR 5.6–9.0 years). We excluded the small number
of participants who reported race other than white
or black (n=48), participants with prevalent diabetes
defined as in CARRS above (n=1867) and those who
were missing diabetes status (n=882). We also excluded
those who were under the age of 45 at visit 1 (n=35). A
total of 6351 participants had fasting glucose (at baseline) between 100 and 125 mg/dL or HbA1c (at visit 2)
between 5.7% and 6.5%. A total of 12 983 ARIC participants were included in the analysis (n=3059 blacks and
n=9924 whites).
Measurements
Sociodemographic data, anthropometry (height, weight,
waist circumference), history of smoking, diabetes status,
family history of diabetes and measured systolic (SBP)
and diastolic (DBP) blood pressures were available in
both CARRS and ARIC. For the assessment of blood pressure, in CARRS, participants were rested for 5 min, and
blood pressure was measured twice using an electronic
sphygmomanometer (Omron HEM-7080 and HEM-
7080IT-E; Omron, Tokyo, Japan). A third measurement
was taken if the difference between the first two systolic
or diastolic measurements was >10 or 5 mm Hg, respectively. The mean of last two readings (ie, second and
third reading) was used for analysis. In ARIC, SBP and
DBP were measured three times per participant using
BMJ Open Diab Res Care 2021;9:e001927. doi:10.1136/bmjdrc-2020-001927
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a standardized Hawksley random-zero instrument. The
mean of the second and third measurement was used.
FPG was measured by hexokinase/kinetic method
in Chennai and Delhi site and by glucose oxidase/end
point method in Karachi in CARRS. HbA1c was measured
by high-
performance liquid chromatography (HPLC)
method in all three sites with reagents from Bio-Rad Laboratories, Hercules, California, USA certified by National
Glycohemoglobin Standardization Program (NGSP) and
traceability to Diabetes Control and Complications Trial.
In ARIC, glucose was assayed by a hexokinase method in
serum at visits 1 and 2 and in plasma at visits 3 and 4.
Persons fasting <8 hours were excluded from baseline and
follow-up. HbA1c was measured from frozen whole-blood
samples collected at ARIC visit 2 only and were assayed
using HPLC (Tosoh A1c 2.2 Plus Glycohemoglobin
Analyzer method in 2003–2004 and Tosoh G7 method
in 2007–2008, Tosoh, Tokyo, Japan) and standardized
to the Diabetes Control and Complications Trial assay.22
Serum insulin was measured at visit 1 by radioimmunoassay using an Insulin Kit (Cambridge Medical Diagnosis,
Billerica, Massachusetts, USA). Among CARRS, serum
insulin concentration was measured using the electrochemiluminesence method (COBAS E 411; Roche Diagnostics), and validation of CARRS insulin measurements
against a US reference laboratory, the Northwest Lipid
Metabolism and Diabetes Research Laboratories have
been reported earlier.23
In both cohorts, lipids (low-
density lipoprotein-
cholesterol (LDL-c), high-density lipoprotein-cholesterol
(HDL-c), triglycerides) were measured in fasting serum;
LDL-
c was calculated using the Friedewald equation,
except when triglycerides were >4.52 mmol/L (400 mg/
dL). BMI was calculated as measured weight in kilograms divided by measured height in meter squared.
BMI was categorized as <25; 25–29.9 and ≥30 kg/m2
(normal weight, overweight and obese). Homeostasis
model assessment of insulin resistance (HOMA-IR) was
calculated as=fasting insulin (µIU/L)×fasting glucose
(nmol/L)/22.5 or (I0 (µIU/mL)×G0 (mmol/L)/22.5);
and homeostasis model assessment of β-cell dysfunction (HOMA-
B) for insulin secretion was calculated
as=(20×insulin)/(glucose−3.5) or (20×I0 (µIU/mL)/G0
(mmol/L)−3.5).24
Incident diabetes
In the CARRS and ARIC cohorts, incident diabetes was
defined as FPG ≥7.00 mmol/L (126 mg/dL), HbA1c
≥6.5% (48 mmol/mol) or self-reported/physician diagnosed diabetes or on medication during follow-
up.
Additional analyses using only the FPG criteria was also
undertaken.
Statistical analysis
Baseline characteristics among South Asians, US blacks
and US whites were compared. Data were presented as
mean (SD), median (IQR) or percentages as appropriate.
The median test was used to compare the difference in
BMJ Open Diab Res Care 2021;9:e001927. doi:10.1136/bmjdrc-2020-001927

median values between South Asians versus US blacks
and South Asians versus US whites. To compare the
difference in proportions, χ2 test was used. Per cent incidence rates with 95% CIs were computed. Person-years
were estimated from the date of enrolment to the time
of diabetes diagnosis or the last date of visit or death,
whichever was documented earlier. Age-
specific incidence (cases/1000 person-
years) by sex and ethnicity
was calculated. Age-standardized diabetes incidence (per
1000 person-years) using the world age distribution by
sex25 was also reported.
BMI-
specific incidence (cases/1000 person-
years)
of diabetes, adjusted for age and stratified by sex and
ethnicity, was calculated using Poisson models. The relative risk (incidence rate ratio (IRR)) and absolute risk
(incidence rate difference (IRD)) comparing South
Asians or US blacks minus US whites (US whites as
referent group) and 95% CIs were estimated. Multivariable Cox proportional hazards models were used to assess
the associations of HOMA-IR and HOMA-B with incident diabetes, separately in CARRS and ARIC. We tested
for linear association of incident diabetes with age and
BMI. Unlike BMI, age did not have a linear association
with diabetes. Therefore, in the final adjusted model we
included age and a quadratic term for age, gender, BMI,
HOMA-IR (z-score) and HOMA-B (z-score). Proportionality hazards assumptions (proportionality, interaction
among predictors, time dependence) were evaluated,
and were satisfied.
We conducted supplementary analyses among
those without self-
reported diabetes and with FPG
<7.00 mmol/L (126 mg/dL) at baseline, with incident
diabetes defined as those with FPG ≥7.00 mmol/L (126
mg/dL), or self-reported/physician-diagnosed diabetes,
or medication use at any time during follow-
up. We
undertook these supplementary analyses as HbA1c may
vary by ethnicity.
All analyses were conducted using Stata V.16.0 (College
Station, Texas, USA).
RESULTS
At baseline (table 1), the median age (years) of South
Asians, US blacks and US whites were comparable (52.0
vs 52.0 vs 54.0). Overall, South Asians had lower median
c,
BMI and waist circumference, lower levels of HDL-
LDL-c, higher levels of triglycerides, SBP, DBP and lower
fasting insulin than blacks and whites and there was
significant difference between South Asian versus blacks
and South Asian versus whites (table 1). South Asians
were less insulin resistant than blacks and whites (age-
BMI-adjusted HOMA-IR, µIU/mL/mmol/L: 2.30 vs 3.45
vs 2.59, South Asian vs blacks p<0.001; South Asian vs
whites p<0.001), South Asians were secreting less insulin
than blacks but not whites (age-BMI-adjusted HOMA-B,
µIU/mL/mmol/L: 103.7 vs 140.6 vs 103.9, South Asian
vs blacks p<0.001, South Asian vs whites p=0.9305)
(figure 1).
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Table 1 Characteristics of study populations without diabetes in the CARRS (2010–2011) and ARIC (1987–1989) cohorts
Variables

South Asians (n=3136)

US blacks (n=3059)

US whites (n=9924)

52.0 (48.0, 58.0)

54.0 (49.0, 59.0)†

Age, years

52.0 (47.0, 60.0)

Age categories (years), (%)

 

 45–49

36.4

34.6‡

26.0†

 49–54

22.5

26.8

26.6

 55–59

14.2

21.2

25.1

 ≥60

26.8

17.5

22.3

Men, (%)

52.7

37.8‡

46.6†

Current smoker, (%)

16.9

29.7‡

23.9†

Current drinker, (%)

14.4

33.8‡

66.3†

Family (parental) history of diabetes, (%)

17.2

24.7‡

21.9†

BMI, kg/m2

24.9 (21.7, 28.4)

28.2 (25.1, 32.1)‡

26.0 (23.4, 29.1)†

BMI categories, kg/m2 (%)

 

 <25.0

50.6

23.8‡

39.4†

 25.0–29.9

32.4

39.6

40.4

 ≥30

17

36.6

20.2

Waist, cm

87.5 (79.0, 96.0)

96.0 (88.0, 106.0)‡

95.0 (86.5, 103.0)†

HbA1c, mmol/mol*

40.0 (37.0, 42.0)

39 (36.0, 42.0)‡

36 (33.0, 38.0)†

HbA1c, %*

5.8 (5.5, 6.0)

5.7 (5.4, 6.0)‡

5.4 (5.2, 5.6)†

FPG, mmol/L

5.27 (4.94, 5.66)

5.44 (5.08, 5.82)‡

5.44 (5.13, 5.77)†

Triglycerides, mmol/L

1.36 (1.03, 1.85)

1.02 (0.77, 1.40)‡

1.25 (0.90, 1.79)†

LDL-c, mmol/L

2.98 (2.43, 3.52)

3.45 (2.78, 4.21)‡

3.50 (2.91, 4.52)†

HDL-c, mmol/L

1.11 (0.96, 1.32)

1.37 (1.14, 1.70)‡

1.27 (1.02, 1.57)

SBP, mm Hg

126.0 (114.5, 140.5)

124.0 (113.0, 137.0)‡

116.0 (106.0, 127.0)†

DBP, mm Hg

83.0 (76.0, 91.0)

79.0 (72.0, 87.0)‡

71.0 (65.0, 78.0)†

Fasting insulin, pmol/L§

56.3 (36.8, 83.3)

79.2 (50.0, 114.6)‡

57.6 (43.1, 86.1)

HOMA-IR, µIU/mL×mmol/L,

1.9 (1.2, 3.0)

2.7 (1.8, 4.3)‡

2.1 (1.4, 3.2)†

HOMA-B, µIU/mL/mmol/L,

87.6 (59.6, 129.7)

118.7 (78.8, 172.4)‡

90.1 (62.0, 127.4)†

Data are presented as median (IQR Q1, Q3) or %.
Diabetes defined as FPG ≥7.00 mmol/L (126 mg/dL) or HbA1c ≥48 mmol/mol (6.5%) or self-reported/physician-diagnosed diabetes or medication.
P value calculated using median test for comparing median values and χ2 test for categorical variables.
HOMA-B=(20×insulin)/(glucose−3.5) or (20×I0 (µIU/mL)/G0 (mmol/L)−3.5). HOMA-IR=fasting insulin (µIU/L)×fasting glucose (nmol/L)/22.5 or (I0 (µIU/
mL)×G0 (mmol/L)/22.5).
Family history=diabetes mellitus in father or mother.
*HbA1c in US blacks and whites was assessed 3 years after baseline in 1990–1992.
†Shows significant difference between South Asians versus US whites.
‡Shows significant difference between South Asians versus US blacks.
§Insulin in South Asians only in Chennai and Delhi samples (n= 1835).
ARIC, Atherosclerosis Risk in Communities; BMI, body mass index; CARRS, Center for Cardiometabolic Risk Reduction in South Asia Study; DBP,
diastolic blood pressure; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; HDL-c, high-density lipoprotein-cholesterol; HOMA-B, homeostasis
model assessment of β-cell dysfunction; HOMA-IR, homeostatic model assessment of insulin resistance; LDL-c, low-density lipoprotein-cholesterol;
ns, not significant; SBP, systolic blood pressure.

The median (IQR) duration of follow for South Asians,
blacks and whites was 4.8 (3.8, 5.1); 8.6 (5.6, 8.8) and 8.9
(8.7, 9.0), respectively. Among 3136 South Asians without
diabetes at baseline (52.5% men), 389 incident cases
of diabetes developed during the follow-up (table 2).
Among 3059 US blacks without diabetes at baseline
(37.8% men), 588 incident cases of diabetes developed
during the follow-up, and among 9924 US whites without
diabetes (46.6% men), 1036 incident cases of diabetes
developed during the follow-up.
Age-
standardized diabetes incidence (cases/1000
person-years, 95% CI) in South Asian men was similar to
4

US black men, but higher compared with US white men
(IRR (95% CI) 26.0 (22.2 to 29.8) vs 26.2 (22.7 to 29.7) vs
16.1 (14.8 to 17.4), respectively). In women, South Asians
had a slightly higher incidence of diabetes compared with
US black women (IRR (95% CI) 31.9 (27.5 to 36.2) vs 28.6
(25.7 to 31.6) vs 11.3 (10.2 to 12.3), respectively). The
diabetes incidence was 1.6 times higher in South Asian
men (IRR (95% CI) 1.62 (1.37 to 1.92)) as compared
with US white men but approximately 3 times higher in
South Asian women (IRR (95% CI) 3.09 (2.61 to 3.66)) as
compared with US white women. The absolute risk difference of incident diabetes (cases/1000 person years) was
BMJ Open Diab Res Care 2021;9:e001927. doi:10.1136/bmjdrc-2020-001927
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and US blacks. Family history of diabetes was significantly associated with incident diabetes among black and
white Americans but not among South Asians. For the
association with diabetes, South Asians had the lowest
HR for HOMA-IR (HR for 1 SD (95% CI) South Asian:
2.67 (2.05 to 3.48); blacks: 14.55 (11.11 to 19.07); whites:
34.64 (27.63 to 43.42)) and largest HR for HOMA-B (HR
(95% CI) South Asian: 0.44 (0.34 to 0.58); blacks: 0.08
(0.06 to 0.11); whites: 0.05 (0.04 to 0.06)).
Patterns of association were similar in sensitivity analyses using a more specific definition of diabetes based
on FPG ≥7.00 mmol/L (126 mg/dL) or glucose-lowering
medication use (online supplemental table). These additional analyses also confirmed that although HbA1c may
vary by ethnicity and was not available in the ARIC cohort
at the first visit, this did not impact the pattern of differences in diabetes incidence between ethnicities.

Figure 1 Mean values for HOMA-IR (µIU/mL×mmol/L)
and HOMA-B (µIU/mL/mmol/L) adjusted by age and age/
BMI. BMI, body mass index; HOMA-B, homeostasis model
assessment of β-cell dysfunction; HOMA-IR, homeostatic
model assessment of insulin resistance.

higher in South Asian men (IRD (95% CI 10.1 (6.1 to
14.2)) and women (IRD (95% CI) 22.4 (17.8 to 27.0)) as
compared with US white men and women, respectively.
In those with BMI <25 kg/m2 (table 3), risk of diabetes
in men was 3 times higher in South Asians (IRR (95% CI)
2.99 (2.09 to 4.28)) and 2.1 times higher in US blacks
(IRR (95% CI) 2.11 (1.35 to 3.25)) as compared with
US whites. Similarly, in women, the risk of diabetes in
those with BMI <25 kg/m2 was 5.3 times higher in South
Asian (IRR (95% CI) 5.27 (3.64 to 7.54)) and 2.5 times
higher in US blacks (IRR (95% CI) 2.36 (1.56 to 3.78)) as
compared with US whites. The absolute number of incident cases/1000 person-years was higher in South Asian
men (IRD (95% CI) 12.5 (7.7 to 17.2)) and women (IRD
(95% CI 17.9 (11.7 to 24.2)) as compared with US whites
men and women with BMI <25 kg/m2.
In those with BMI ≥30 kg/m2 (table 3), diabetes incidence
in South Asian men was 1.21 (0.76, 1.84) times higher than
in US white men and in South Asian women, diabetes incidence was 2.1 (1.56, 2.74) times higher than in US white
women (table 3). The absolute diabetes risk was higher in
South Asian women than in US white women (IRD (95% CI
17.9 (11.7 to 24.2)) with BMI >30 kg/m2.
In multivariable Cox models (table 4), associations
between age, sex, BMI and family history of diabetes
with diabetes risk were similar in South Asians, US whites
BMJ Open Diab Res Care 2021;9:e001927. doi:10.1136/bmjdrc-2020-001927

DISCUSSION
Our prospective analyses, using data from two well-
established cohorts (the CARRS and ARIC studies),
confirm that South Asian adults living in urban India
and Pakistan are, on average, less obese than blacks and
whites in the USA, yet have higher diabetes incidence
than US whites. This difference was more pronounced in
women compared with men, and was also more marked
in those with low BMI. Contrary to the widely held view
that South Asians have a high propensity to insulin resistance,5 6 26–28 our results are consistent with South Asians
being less insulin resistant than US blacks or whites.
These findings suggest that obesity and insulin resistance
may not be the driving factors behind the high incidence
of diabetes in South Asians, and impaired insulin secretion may be more important.
There are several studies indicating that South Asians
have a higher prevalence of diabetes even at lower BMI
compared with other race/ethnic groups.1–4 A study
assessing diabetes prevalence in New York City by race/
ethnicity noted that South Asians with normal BMI had
nearly five times the diabetes prevalence of comparable
normal weight whites, and more than double the prevalence of overweight whites.2 Similarly, a study assessing
diabetes prevalence by weight category in US immigrants found that normal weight South Asians had nearly
twice the diabetes prevalence of overweight European
immigrants.4 Few studies have also examined the incidence rate of diabetes among South Asians compared
with other race/ethnic groups by BMI category. A study
comparing the incidence rates of diabetes across race/
ethnic groups and BMI strata in Ontario, Canada found
that the incidence rate of diabetes was 3 times higher in
normal weight (BMI 18.5–25 kg/m2) South Asians than in
white Canadians.1 Our study adds further evidence to the
notion that South Asians are at high risk for diabetes at
low BMI by indicating that in those with BMI <25 kg/m2,
the risk of diabetes incidence was 3 and 5.3 times higher
in South Asian men and women, respectively compared
5

BMJ Open Diab Res Care: first published as 10.1136/bmjdrc-2020-001927 on 26 March 2021. Downloaded from http://drc.bmj.com/ on April 12, 2021 at Aga Khan University. Protected by
copyright.

Epidemiology/Health services research

6

BMJ Open Diab Res Care 2021;9:e001927. doi:10.1136/bmjdrc-2020-001927

6939

46

≥60

Total (crude) 183

6228

33

42

55–59

≥60

Total (crude) 206

13 167

916

28.7
(25.8 to 31.5)

29.5
(26.7 to 32.6)

31.9
(27.5 to 36.2)

33.1
(28.9 to 37.9)

29.5
(21.8 to 39.9)

36.0
(25.6 to 50.7)

27.8
(20.3 to 38.1)

37.0
(30.2 to 45.4)

26.0
(22.2 to 29.8)

26.4
(22.8 to 30.5)

22.7
(17.0 to 30.4)

34.5
(24.7 to 48.3)

24.7
(18.0 to 33.8)

27.2
(21.3 to 34.8)

Incidence
(95% CI)
Per 1000 PYR

588

372

62

84

112

114

216

38

49

56

73

New
cases

US blacks

21 618

13 516

2050

2719

3796

4952

8102

1520

1686

2105

2791

PYR

27.6
(25.4 to 29.9)

27.2
(25.1 to 29.5)

28.6
(25.7 to 31.6)

27.5
(24.9 to 30.5)

30.2
(23.6 to 38.8)

30.9
(24.9 to 38.3)

29.5
(24.5 to 35.5)

23.0
(19.2 to 27.7)

26.2
(22.7 to 29.7)

26.7
(23.3 to 30.5)

25.0
(18.2 to 34.4)

29.1
(22.0 to 38.5)

26.6
(20.5 to 34.6)

26.2
(20.8 to 32.9)

Incidence
(95% CI)
Per 1000 PY

1036

453

109

124

114

106

583

137

163

155

128

New cases

US whites

78 294

42 380

8494

10 149

11 617

12 120

35 914

8509

9371

9419

8616

PYR

13.5
(12.7 to 14.3)

13.2
(12.5 to 14.1)

11.3
(10.2 to 12.3)

10.7
(9.7 to 11.7)

12.8
(10.6 to 15.5)

12.2
(10.2 to 14.6)

9.8
(8.2 to 11.8)

8.7
(7.2 to 10.6)

16.1
(14.8 to 17.4)

16.2
(15.0 to 17.6)

16.1
(13.6 to 19.0)

17.4
(14.9 to 20.3)

16.5
(14.1 to 19.3)

14.9
(12.5 to 17.7)

Incidence
(95% CI)
Per 1000 PYR

Diabetes defined as FPG ≥7.0 mmol/L (126 mg/dL) or HBA1c ≥48 mmol/mol (6.5%) or self-reported/physician-diagnosed diabetes or medication.
IRR calculated as South Asians/US blacks (incidence rate) divided by US whites (incidence rate).
IRD, (risk difference, cases/1000 PYR) calculated as South Asians/US blacks (incidence rate) minus US whites (incidence rate).
*Standardised to world population.
FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; IRD, incidence risk difference; IRR, incidence rate ratio; PYR, person-years; ref, reference.

Total (age
standardised*)

Total (crude) 389

Both sexes

Total (age
standardised*)

1426

39

50–54

1400

92

2486

985

45–49

Women

Total (age
standardised*)

2023

34

55–59

1580

39

50–54

2352

PYR

64

New
cases

South Asians (SA)

Age-specific incidence of diabetes (cases/1000 PYR) by sex and ethnicity

45–49

Men

Age
categories
(years)

Table 2

3.19
(2.87 to 3.53)

3.09
(2.61 to 3.66)

2.3
(1.57 to 3.3)

2.95
(1.95 to 4.36)

2.84
(1.92 to 4.12)

4.23
(3.17 to 5.65)

1.62
(1.37 to 1.92)

1.41
(0.99 to 1.99)

1.98
(1.33 to 2.89)

1.50
(1.03 to 2.14)

1.83
(1.34 to 2.49)

IRR

28.9
(25.3 to 32.5)

22.4
(17.8 to 27.0)

16.6
(7.4 to 25.8)

23.8
(11.3 to 36.3)

18.0
(9.1 to 27.0)

28.3
(20.5 to 36.0)

10.1
(6.1 to 14.2)

6.6
(−0.5 to 13.7)

17.1
(5.2 to 29.0)

8.2
(0.10 to 16.4)

12.4
(5.2 to 19.5)

IRD

South Asians versus US whites (ref)

2.06
(1.85 to 2.28)

2.57
(2.24 to 2.96)

2.36
(1.70 to 3.25)

2.53
(1.89 to 3.36)

3.01
(2.30 to 3.94)

2.63
(2.00 to 3.46)

1.64
(1.40 to 1.92)

1.55
(1.05 to 2.24)

1.67
(1.19 to 2.31)

1.62
(1.17 to 2.21)

1.76
(1.30 to 2.36)

IRR

14
(11.6 to 16.3)

16.8
(13.9 to 19.8)

17.4
(9.5 to 25.3)

18.7
(11.7 to 25.6)

19.7
(13.9 to 25.4)

14.3
(9.7 to 18.8)

10.4
(6.6 to 14.2)

8.9
(0.5 to 17.3)

11.7
(3.1 to 20.2)

10.1
(2.7 to 17.6)

11.3
(4.8 to 17.8)

IRD

US blacks versus US whites (ref)
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62

24

25.0–29.9

≥30

67

69

25.0–29.9

≥30

1303

1891

2214

558

1710

3523

PYR

52.8
(40.3 to 65.2)

35.3
(26.8 to 43.8)

22.2
(16.0 to 28.4)

43.0
(25.8 to 60.2)

36.2
(27.2 to 45.3)

18.7
(14.2 to 23.3)

Incidence
(95% CI)

228

115

29

98

83

34

New
cases

5604

5085

2802

1910

3593

2570

PYR

US blacks

40.9
(35.6 to 46.2)

22.7
(18.5 to 26.8)

10.4
(6.6 to 14.1)

51.5
(41.3 to 61.7)

23.2
(18.2 to 28.2)

13.2
(8.7 to 17.6)

Incidence
(95% CI)

209

155

89

242

276

65

New
cases

8190

12 999

21 171

6810

18 712

10 384

PYR

US whites

25.5
(22.1 to 29.0)

11.9
(10.0 to 13.7)

4.2
(3.4 to 5.1)

35.7
(31.2 to 40.2)

14.8
(13.0 to 16.5)

6.3
(4.7 to 7.8)

Incidence
(95% CI)

2.07
(1.56 to 2.74)

2.97
(2.20 to 3.98)

5.27
(3.64 to 7.54)

1.21
(0.76 to 1.84)

2.46
(1.84 to 3.25)

2.99
(2.09 to 4.28)

IRR

27.4
(14.5 to 40.4)

23.5
(14.8 to 32.2)

17.9
(11.7 to 24.2)

7.4
(−10.3 to 25.2)

21.5
(12.3 to 30.7)

12.5
(7.7 to 17.2)

IRD

SA versus US whites (ref)

Age-adjusted incidence reported.
IRR (ratio of incidence rates) calculated as South Asians/US blacks (incidence rate) divided by US whites (incidence rate).
IRD (risk difference, cases/1000 PYR) calculated as South Asians/US blacks (incidence rate) minus US whites (incidence rate).
IRR and IRD calculated from crude incidence rates.
Diabetes defined as FPG ≥7.00 mmol/L (126 mg/dL) or HbA1c ≥48 mmol/mol (6.5%) or self-reported/physician-diagnosed diabetes or medication.
BMI, body mass index; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; IRD, incidence risk difference; IRR, incidence rate ratio; PYR, person-years; ref, reference.

49

<25

Women

66

<25

Men

New
cases

South Asians (SA)

BMI-specific incidence of diabetes (cases/1000 PYR) by sex and ethnicity

BMI
categories

Table 3

1.59
(1.32 to 1.93)

1.9
(1.48 to 2.43)

2.46
(1.56 to 3.78)

1.44
(1.13 to 1.83)

1.57
(1.21 to 2.01)

2.11
(1.35 to 3.25)

IRR

15.2
(8.9 to 21.5)

10.7
(6.2 to 15.2)

6.1
(2.3 to 10.0)

15.8
(4.7 to 26.9)

8.4
(3.1 to 13.6)

7.0
(2.3 to 11.7)

IRD

US blacks versus US whites
(ref)
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Table 4 Factors associated with diabetes incidence by ethnicity, Cox proportional hazards analysis
South Asians

US blacks

US whites

Variables

HR (95% CI)

HR (95% CI)

HR (95% CI)

Age
Age square

0.98 (0.82 to 1.18)
1.00 (1.00 to 1.00)

1.05 (0.77 to 1.43)
1.00 (1.00 to 1.00)

1.03 (0.82 to 1.30)
1.00 (1.00 to 1.00)

Sex (men)

0.89 (0.66 to 1.19)

1.00 (0.83 to 1.20)

0.98 (0.86 to 1.11)

BMI (per unit)

1.05 (1.02 to 1.08)

1.04 (1.02 to 1.05)

1.06 (1.04 to 1.07)

Family (parental) history of diabetes (yes)

1.23 (0.86 to 1.75)

1.37 (1.14 to 1.65)

1.53 (1.35 to 1.75)

Log HOMA-IR (per SD)
Log HOMA-B (per SD)

2.67 (2.05 to 3.48)
0.44 (0.34 to 0.58)

14.55 (11.11 to 19.07)
0.08 (0.06 to 0.11)

34.64 (27.63 to 43.42)
0.05 (0.04 to 0.06)

Diabetes defined as FPG ≥7.00 mmol/L (126 mg/dL) or HbA1c ≥48 mmol/mol (6.5%) or self-reported/physician-diagnosed
diabetes or medication.
BMI, body mass index; FPG, fasting plasma glucose; HOMA-B, homeostasis model assessment of β-cell dysfunction;
HOMA-IR, homeostatic model assessment of insulin resistance; HR, hazard ratio.

with whites. The reasons for the high risk of diabetes in
South Asians is likely multifactorial, reflecting genetic,
epigenetic, lifestyle factors, together with differences in
pathophysiological mechanisms.
While earlier studies have noted high levels of insulin
resistance in South Asians,5 6 26–28 increasing evidence
suggest that South Asians have an innate susceptibility
to defects in insulin secretion. Cross-
sectional studies
from Chennai, India, have noted that South Asians have
reduced insulin secretion, even at mild levels of dysglycemia.29 In young adults, dysfunction in insulin secretion,
more so than insulin resistance, appears to be closely
associated with diabetes.30 As South Asian adults have
impaired early phase insulin release, consistently across
all weight status classes, as reflected in the first 30 min of
an oral glucose tolerance test, existing evidence suggests
that pathways of disease development may emphasize
pathways related to deficient insulin secretion, impaired
fasting glucose and possibly exacerbated by ectopic
hepatic and intramyocellular fat accumulation.23 31 A
study assessing the associations of insulin secretion and
insulin resistance on glycemic status in South Asians
living in the USA found that after accounting for visceral
fat, poor insulin secretion was more strongly associated
with hyperglycemia than was insulin resistance.32 In our
study, we found that South Asians were less insulin resistant than both whites and blacks, and less insulin secretion than black participants. This coupled with the high
incidence rates of diabetes in South Asians adds further
evidence that insulin secretion may be the primary and
relatively more important defect driving diabetes risk in
this race/ethnic population. This has major implications
for ethnicity-specific diabetes treatment guidelines.33
Our study has several limitations that should be taken
into account in interpreting these results. Although both
CARRS and ARIC were population-based cohorts, they
were assembled at different time period using different
sampling methodologies, and also CARRS was purely
urban, while ARIC was largely urban and suburban.
Our comparison of diabetes incidence in South Asians
8

with blacks and whites was restricted to ages ≥45 years
as the ARIC cohort only recruited people aged 45 years
and over. This limits our ability to examine the differences between younger South Asians and comparably
aged blacks and whites, which may be important as
South Asians have high diabetes prevalence at younger
ages.13 15 34 35 Indeed, at baseline in our analysis, South
Asians had a higher prevalence of diabetes, and thus we
may be underestimating diabetes incidence in this cohort
as a smaller at-
risk group was followed. However, we
found that across all ages from 45 years up, South Asians
had a higher diabetes incidence than whites, and this was
especially marked at lower BMIs. Our analysis primarily
relied on BMI as a measure of body composition, and this
measure does not fully capture body fat distribution.36–38
However, additional analysis using waist circumference
(online supplemental table S5) as a measure of central
adiposity found similar differences between South Asians
and blacks and whites in diabetes incidence across the
distribution of adiposity.
To ensure comparability of end points, we used the
same definition of diabetes across the two studies and
relied on person-years of follow-up to standardize incidence estimates. In ARIC, HbA1c was not available at
baseline; however, sensitivity analyses restricting the
comparison to only self-
reported diabetes or fasting
blood glucose ≥7.00 mmol/L (126 mg/dL) found similar
patterns of differences between the ethnic groups. A
limitation was that the CARRS and ARIC cohorts were
initiated at different time periods and have some differences in follow-up, but our primary measure is incidence
per 1000 person-years, and the focus of our comparison
is around biological variables. Furthermore, the rise in
diabetes in low-
income and middle-
income countries,
like India and Pakistan, has happened over the past two
decades, and no earlier cohorts exist.
Our study also has significant strengths. Both CARRS
and ARIC are well-established and well-retained cohort
studies of high quality, with standardized data collection, and multiple time points of follow-up for rigorous
BMJ Open Diab Res Care 2021;9:e001927. doi:10.1136/bmjdrc-2020-001927
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assessment of diabetes. Our study also examined diabetes
incidence across the full distribution of BMI, used
rigorous capture of incident diabetes and had longitudinal follow-
up. Furthermore, we included measures
of insulin resistance and secretion (ie, HOMA-IR and
HOMA-B), which are validated against gold standards,
and are considered reasonable for population studies.39 40
In conclusion, in this study of prospective data from
two longitudinal cohorts, we found that the incidence
of diabetes among South Asian adults is higher than US
whites, and markedly so in people without obesity. Our
results are also consistent with South Asians being less
insulin resistant than US blacks or whites. Factors other
than obesity and insulin resistance (eg, innate insulin
deficiency) may thus be important in the risk of diabetes
in South Asians. Screening, prevention and treatment
guidelines may need to be tailored more appropriately to
address the mechanisms of disease risk in South Asians.
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